Form 4: Insider Trading: Cohen Sells ImmunityBio Shares

Cheryl Cohen, a Director at ImmunityBio, Inc., reported transactions involving the sale of company stock.

Summary

• Cheryl Cohen, a Director at ImmunityBio, Inc. (IBRX), reported a series of stock transactions on July 2, 2026.
• These transactions include the acquisition of 55,979 shares of common stock at $2.98 per share, and the disposal of 131,210 shares at a weighted average price of $9.50 to $9.52.
• The sale of shares was executed under a Rule 10b5-1 trading plan established on February 27, 2026.
• Following these transactions, Cohen beneficially owns 125,386 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative sentiment due to the significant sale by a Director, despite the transaction being conducted under a pre-planned Rule 10b5-1 trading plan.

Positives

• The sale of shares was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to immediate negative news.
• The acquisition of shares at a lower price point ($2.98) could be interpreted as a strategic move by the insider.

Negatives

• A significant number of shares (131,210) were sold by a Director, which could be perceived negatively by the market.
• The sale price ($9.50-$9.52) is substantially higher than the acquisition price ($2.98), indicating a considerable profit for the reporting person.

Risks

• Potential for negative market perception due to a Director's significant stock sale.
• The Rule 10b5-1 plan, while providing a defense against insider trading allegations, still represents a divestment of ownership by a key insider.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing.

Management Comments

• The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on February 27, 2026.
• Represents the weighted average share price of an aggregate total of 131,210 shares sold in the price range of $9.50 to $9.52 by the Reporting Person.
• The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that insider selling, especially under a Rule 10b5-1 plan, is a common occurrence. However, the magnitude of the sale by a Director warrants attention, particularly in the biotechnology sector where stock performance can be volatile and heavily influenced by news and clinical trial results.

Stakeholder Impact

• Shareholders may view the sale by a Director as a potential signal of reduced confidence, although the Rule 10b5-1 plan mitigates concerns about opportunistic trading.
• Employees may also interpret the insider sale, but the pre-planned nature of the transaction is a mitigating factor.

Next Steps

• The reporting person may provide further details on individual share sale prices upon request from regulatory bodies or security holders.

Key Dates

Recommendation

The filing indicates a significant sale by a Director, which is a negative signal. However, the sale was executed under a pre-established Rule 10b5-1 trading plan, which is a standard and legally compliant method for insiders to diversify their holdings without implying adverse non-public information. The acquisition of shares at a lower price point is a neutral to slightly positive indicator. Given these factors, a 'hold' recommendation is appropriate, suggesting investors monitor further company developments and insider activity.

Keywords

Insider Trading, Form 4, ImmunityBio, IBRX, Stock Sale, Rule 10b5-1, Cheryl Cohen, Director, Beneficial Ownership